GlassScriptPhysician profile
Robert F Silzer
NPI 1881626257
$13,759.49
in general payments reported to CMS, 2019-2025
50 companies · $4,856 in 2025
The $4,856 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $393 · 2021: $491 · 2022: $769 · 2023: $2,313 · 2024: $4,166 · 2025: $4,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $58.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,276.21 |
| Education | $58.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,362.43 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $1,619.65 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Emd Serono, INC. | $830.54 | 2019-2025 | Mavenclad |
| Amgen INC. | $813.77 | 2019-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $809.84 | 2019-2025 | |
| Tg Therapeutics, INC. | $767.59 | 2023-2025 | |
| Lundbeck LLC | $521.92 | 2020-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $497.52 | 2019-2025 | Ultomiris, Soliris |
| Kedrion Biopharma, INC. | $421.13 | 2023-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Pfizer INC. | $380.59 | 2023-2025 | |
| Argenx US, INC. | $368.16 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $354.87 | 2020-2025 | Hizentra |
| Amneal Pharmaceuticals LLC | $347.48 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Biogen, INC. | $331.70 | 2019-2025 | Vumerity, Spinraza, Tysabri |
| Neurocrine Biosciences, INC. | $302.60 | 2022-2025 | Ingrezza, Ongentys |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $255.39 | 2023-2025 | Apokyn, Gocovri, Gocovri |
| Tanabe Pharma America, INC. | $229.38 | 2019-2024 | |
| Lilly USA, LLC | $223.52 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Merz Pharmaceuticals, LLC | $220.15 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Eisai INC. | $212.20 | 2023-2025 | |
| Celgene Corporation | $206.23 | 2023-2025 | Zeposia |
| Boston Scientific Corporation | $140.53 | 2023 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $127.80 | 2024-2025 | Solitaire X |
| Takeda Pharmaceuticals U.S.A., INC. | $111.81 | 2025 | Hyqvia |
| Genentech USA, INC. | $111.25 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Ipsen Biopharmaceuticals, INC | $100.62 | 2024-2025 | Dysport |
| Genzyme Corporation | $98.14 | 2019 | |
| Allergan, INC. | $95.39 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $95.00 | 2023 | Gammaplex, Coagadex |
| Sk Life Science, INC. | $93.32 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $78.78 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $70.99 | 2021 | |
| Neurelis, INC. | $67.60 | 2023-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $57.31 | 2020-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $52.32 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $40.17 | 2025 | Wainua |
| Catalyst Pharmaceuticals, INC. | $38.35 | 2022-2024 | |
| Kyowa Kirin, INC. | $34.89 | 2024 | Nourianz |
| Acadia Pharmaceuticals INC | $30.71 | 2023-2025 | Nuplazid |
| Grifols USA, LLC | $27.75 | 2025 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $25.28 | 2021 | |
| Horizon Therapeutics Plc | $24.21 | 2023 | Uplizna |
| Merz North America, INC. | $23.42 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.19 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.79 | 2021 | |
| Ge Healthcare | $21.15 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.36 | 2024 | Amvuttra |
| Nevro Corp. | $18.02 | 2024 | Senza |
| Vertical Pharmaceuticals, LLC | $17.57 | 2020 | |
| Corium, LLC | $17.11 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Silzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.